Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.60
Bid: 2.50
Ask: 2.70
Change: -0.05 (-1.89%)
Spread: 0.20 (8.00%)
Open: 2.65
High: 2.65
Low: 2.60
Prev. Close: 2.65
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Arecor Therapeutics wins patent approval in US

Wed, 23rd Mar 2022 20:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hydrogen Utopia International PLC - London-based company specialising in turning non-recyclable mixed waste plastic into carbon-free fuels - Says it believes that building new waste plastic to energy plants could be "significant" in allowing local communities across Europe to lessen the impacts of the gas and energy supply crisis and the anticipated market changes brought about by ongoing sanctions against Russia and the reluctance to rely upon it as an energy supplier in the future.

----------

ValiRx PLC - Nuneaton, England-based drug development company - Reports it is progressing towards the completion of its proposed sub-licence of VAL201 to TheoremRx Inc. VAL201's primary indication is for prostate cancer, with potential further research & development in breast and ovarian cancer. Company says TheoremRx continues to make good progress with its financing but notes that current global macro-economic events have impacted the timelines. First payments to ValiRx are expected on or before the end of June.

----------

Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Wins patent grant from US Patent & Trademark Office protecting novel formulations of the group's insulin products, AT247 and AT278. Chief Scientific Officer Jan Jezek says: "This recently granted US patent, the first within the group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress."

----------

GENinCode PLC - Manchester-based genetic testing company - Collaborates with Indiana University School of Medicine on a study using its Cardio inCode-SCORE for the risk assessment of patients for onset of atherosclerotic cardiovascular disease.

----------

88 Energy Ltd - oil exploration company focused on Alaska - Reaches total depth of 7,334 feet at Merlin-2 well and ceases drilling. Company says all three target reservoirs at the well were penetrated with elevated gas readings. Adds observations of cutting samples have revealed oil shows over all targets. Wireline logging is due to commence shortly.

----------

i(x) Net Zero PLC - Jersey-based investment company focused on sustainability - Says portfolio company Context Labs has secures a multi-year partnership with energy company Williams Co Inc. Partnership for the deployment of its Immutably-based Decarbonization as a Service platform. The deployment of the enterprise data fabric solution will facilitate Williams' energy transition, i(x) explains.

----------

All Star Minerals PLC - Haywards Heath, England-based mining services investor - Appoints Jason Brewer as chief executive officer. Current CEO Ian Harebottle reverts to the position of non-executive director with immediate effect. Says restructuring has been driven by "recent developments in Europe".

----------

Panther Metals PLC - mineral exploration company focused on Canada - Notes announcement of Panther Metals Ltd, in which it has 37% holding, detailing "significant" reverse circulation drilling sample assay results. Results from the Coglia nickel cobalt project in Western Australia include: 21 metres at 1.34% nickel from 72 metres and 10 metres at 1.3% nickel from 62 metres. 18 of the 26 holes assayed return results above 0.5% nickel and 500 parts per million of copper. Once drilling is complete at Coglia the drill rig will move to the Eight Foot Well gold prospect, the company adds.

----------

Cohort PLC - Reading, England-based technology company - Says its German subsidiary ELAC Sonar has been awarded a contract to supply hydroacoustic equipment by Fassmer Shipyard, on behalf of the Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support. Contract is worth EUR4 million and is expected to complete in the final quarter of 2023.

----------

Tern PLC - London-based investor focused on the internet of things - Notes that Wyld Networks AB has received a purchase order for its Wyld Connect internet of things module from an unnamed Brazilian company in the forestry sector. Tern holds 59% of Wyld Networks.

----------

Capital Metals PLC - London-based mineral sands explorer - Says IHC Mining is nearing the completion of the development study for the Eastern Minerals project in Sri Lanka. Capital Metals expects the final report by mid-April. Adds that drill samples from the project are continuing to be assayed by an independent laboratory but warns of backlogs. Company working with Sri Lankan government to secure industrial mining license but says timeline is beyond their control. Discussion regarding offtake and strategic party agreements continue.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
10 Jun 2014 10:00

ValiRx Submits Application For VAL201 Cancer Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a phase I/II extended clinical study, or trial, of VAL201 in people with cancer. VAL201 is ValiRx's leading anti-cancer therapeutic candidate.

Read more
10 Jun 2014 09:45

Tuesday broker round-up UPDATE

ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy. Avon Rubber: Investec lowers target price from 690p to 680p and downgrades from buy to add. BAE Systems: Investec downgrades from add to hold with a target price of 430p. BG Group: Exane downgrades to neu

Read more
15 May 2014 13:31

ValiRx Sees Progress On Cancer Drug Development From Joint Venture

LONDON (Alliance News) - ValiRx PLC said Thursday that it had seen promising progress on the development of its cancer treatment VAL401 towards Phase II trials since the formation of its joint venture with Tangent Reprofiling Ltd, ValiSeek. The joint venture was formed a month ago to progre

Read more
1 May 2014 10:15

ValiRx Granted Patent For Cancer Screening Biomarker In Japan

LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3. The biomarker was acquired by the company's subsidiary ValiFinn Oy in 2012. As a result, ValiRx now has patent protection on this biomarker i

Read more
8 Apr 2014 11:05

ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development

LONDON (Alliance News) - ValiRx PLC Tuesday said it has established a risk-sharing joint venture with Tangent Reprofiling Ltd which will progress Tangent's VAL401 potential cancer drug through its remaining preclinical development and towards Phase II trials. ValirX said it has acquired a 6

Read more
1 Apr 2014 09:22

ValiRx Anti-Cancer Compound To Undergo Further Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further stability and sterility study to allow for the acceleration towards a Phase 2 efficacy study. ValiRx said it had accepted the advice of the tea

Read more
19 Mar 2014 12:10

ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme

LONDON (Alliance News) - Biotechnology company ValiRx PLC Wednesday posted a widened pretax loss in 2013 as revenue declined, and it upped investment in the clinical trial programme for its anti-cancer therapeutic VAL201. The company posted a pretax loss of GBP2.9 million, widened from GBP2

Read more
20 Feb 2014 11:10

ValiRx Biomarket Receives European Patent Approval

LONDON (Alliance News) - ValiRx PLC Thursday said a cancer screening test gene biomarker called NAV3, acquired by its subsidiary in 2012, has received patent approval from the European Patent Office. In a statement, ValiRx said the latest approval means it has biomarker patent protection in

Read more
31 Jan 2014 13:03

ValiRx Sells Shares In VolitionRx For USD601,578

LONDON (Alliance News) - ValirRx PLC Friday said it has sold its shareholding in VolitionRx to an unnamed firm for USD601,578 and will use the proceeds for the continuing clinical development of its anti-cancer therapeutics VAL101 and VAL201. The life science company had 510,811 shares in c

Read more
27 Dec 2013 08:27

ValiRx Raises GBP2.9 Million In Placing To Fund Oncology Work

Read more
28 Nov 2013 12:27

CORRECT: AIM IN BRIEF: Herstal Emerges As Favourite To Acquire Manroy

Read more
28 Nov 2013 08:22

AIM IN BRIEF: Beretta Emerges As Favourite To Acquire Manroy

Read more
15 Nov 2013 12:39

CORRECT: ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

Read more
15 Nov 2013 12:37

UK WINNERS & LOSERS: IAG Dives Despite Raising Profit Guidance

Read more
15 Nov 2013 10:28

ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.